Skip to main content
SpringerLink
Log in

Quetiapine

Dose-Response Relationship in Schizophrenia

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Quetiapine is a widely used second-generation antipsychotic that is effective in the treatment of schizophrenia and bipolar mania. In recent years, various publications have suggested the possibility that, in some patients, higher than licensed dosages are necessary for full therapeutic effect. A ‘high-dose’ theory of quetiapine activity has developed, leading many prescribers to disregard the formal upper limit of the quetiapine dosage range (750 or 800 mg/day, depending on local labelling).

In this review, we examine the clinical and neuroimaging data relating to the use of quetiapine in acute exacerbations of schizophrenia. Fixed-dose efficacy studies of immediate-release (IR) quetiapine suggest dosages of quetiapine of 150–450 mg/day are more effective than placebo and no less effective than dosages of 600 or 750 mg/day. A fixed-dose study of extended-release quetiapine indicated that dosages of 600 and 800 mg/day were equally efficacious and numerically superior to 400 mg/day. Dosages of IR quetiapine averaging between 254 and 525 mg/day have been shown to be equivalent in efficacy to standard dosages of conventional and other atypical antipsychotics. Pooled data support these findings. Effectiveness studies using quetiapine in daily doses averaging between 565 and 653 mg revealed quetiapine to be somewhat less effective than some comparator drugs.

Support for the use of high-dosage quetiapine (>800 mg/day) is very limited: case reports, albeit numerous, describe quetiapine as showing therapeutic effects only at dosages above the licensed range; some data suggest widespread use of higher dosages in practice; and neuroimaging data suggest inadequate dopamine receptor occupancy at standard dosages (although these findings may reflect the low affinity of quetiapine for dopamine receptors).

Overall, robust controlled data strongly suggest that the standard dosage range for quetiapine is appropriate for clinical use. The balance of evidence does not support the belief that higher dosages are required for full therapeutic effect, although higher dosage trials are ultimately required to confirm or refute this hypothesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII
Table VIII
Table IX
Fig. 1

Similar content being viewed by others

References

  1. Citrome L, Jaffe A, Levine J, et al. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psychiatry 2005; 66(12): 1512–6

    Article  PubMed  Google Scholar 

  2. Pierre JM, Wirshing DA, Wirshing WC, et al. High-dose quetiapine in treatment refractory schizophrenia. Schizophr Res 2005; 73(2-3): 373–5

    Article  PubMed  Google Scholar 

  3. Khazaal Y, Tapparel S, Chatton A, et al. Quetiapine dosage in bipolar disorder episodes and mixed states. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(3): 727–30

    Article  PubMed  CAS  Google Scholar 

  4. Bobes J, Garcia-Portilla MP, Saiz PA, et al. High degree of tolerability for monotherapy with high doses of quetiapine: a case report. J Clin Psychiatry 2002; 63(11): 1048–9

    Article  PubMed  Google Scholar 

  5. Hazra M, Culo S, Mamo D. High-dose quetiapine and photopsia. J Clin Psychopharmacol 2006; 26(5): 546–7

    Article  PubMed  Google Scholar 

  6. Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42(4): 233–46

    CAS  Google Scholar 

  7. Guy W. The clinical global impressions scale. In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rev. ed. Rockville (MD): National Institute of Mental Health, 1976: 157–69

    Google Scholar 

  8. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10(799): 799–812

    Article  Google Scholar 

  9. Kahn RS, Schulz SC, Palazov VD, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68(6): 832–42

    Article  PubMed  CAS  Google Scholar 

  10. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2): 261–76

    Article  PubMed  CAS  Google Scholar 

  11. Pirie W. Jonckheere tests for ordered alternatives. In: Kotz S, Johnson NL, editors. Encyclopedia of statistical sciences. New York: John Wiley and Sons, Inc., 1983: 315–8

    Google Scholar 

  12. King DJ, Link CG, Kowalcyk B. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology 1998; 137(2): 139–46

    Article  PubMed  CAS  Google Scholar 

  13. Barzega G, Bogetto F, Maina G, et al. Quetiapine in schizophrenic patients: a high- and low-dose double-blind comparison. Eur J Psychiatry 2000; 14(4): 221–32

    Google Scholar 

  14. Andreasen N. Scale for the assessment of negative symptoms (SANS). Br J Psychiatry 1989; 155Suppl. 7: 53–8

    Google Scholar 

  15. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54(6): 549–57

    Article  CAS  Google Scholar 

  16. Fabre Jr LF, Arvanitis L, Pultz J, et al. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995; 17(3): 366–78

    Article  PubMed  Google Scholar 

  17. Small JG, Kolar MC, Kellams JJ. Relationship between quetiapine dose and efficacy. Eur Neuropsychopharmacol 2002; 12Suppl. 3: 277

    Article  Google Scholar 

  18. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebocontrolled trial in patients with schizophrenia. US SEROQUEL Study Group. J Clin Psychopharmacol 1996; 16(2): 158–69

    Article  CAS  Google Scholar 

  19. Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000; 30(1): 95–105

    Article  PubMed  CAS  Google Scholar 

  20. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001; 23(11): 1839–54

    Article  PubMed  CAS  Google Scholar 

  21. Zhong KX, Sweitzer DE, Hamer RM, et al. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 2006; 67(7): 1093–103

    Article  PubMed  CAS  Google Scholar 

  22. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96(4): 265–73

    Article  PubMed  CAS  Google Scholar 

  23. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6(4): 278–96

    Article  PubMed  CAS  Google Scholar 

  24. Margolese HC, Chouinard G, Beauclair L, et al. Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2002; 22(4): 347–52

    Article  PubMed  CAS  Google Scholar 

  25. Velligan DI, Prihoda TJ, Sui D, et al. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry 2003; 64(5): 524–31

    Article  PubMed  CAS  Google Scholar 

  26. Sacchetti E, Panariello A, Regini C, et al. Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial. Schizophr Res 2004; 69(2-3): 325–31

    Article  PubMed  Google Scholar 

  27. Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000; 15(3): 121–31

    Article  CAS  Google Scholar 

  28. Hellewell JS. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 1999; 60 Suppl. 23: 14–9

    Google Scholar 

  29. Gefvert O, Bergstrom M, Langstrom B, et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology 1998; 135(2): 119–26

    Article  PubMed  CAS  Google Scholar 

  30. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57(6): 553–9

    Article  PubMed  CAS  Google Scholar 

  31. Tauscher-Wisniewski S, Kapur S, Tauscher J, et al. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 2002; 63(11): 992–7

    Article  PubMed  CAS  Google Scholar 

  32. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors: implications for atypical antipsychotic action. J Psychiatry Neurosci 2000; 25(2): 161–6

    PubMed  CAS  Google Scholar 

  33. Kessler RM, Ansari MS, Riccardi P, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006; 31(9): 1991–2001

    Article  PubMed  CAS  Google Scholar 

  34. Tauscher J, Kufferle B, Asenbaum S, et al. Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine. Psychopharmacology 1997; 133(1): 102–5

    Article  PubMed  CAS  Google Scholar 

  35. Gefvert O, Lundberg T, Wieseigren IM, et al. D2 and 5HT2 receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 2001; 11(2): 105–10

    Article  PubMed  CAS  Google Scholar 

  36. Nagy J. Efficacy, safety and tolerability of quetiapine: short-term high doses with long-term follow-up. Int J Psychiatry Clin Pract 2005; 9(1): 16–21

    Article  CAS  Google Scholar 

  37. Vesely C, Kufferle B, Brucke T, et al. Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine. Int Clin Psychopharmacol 2000; 15(1): 57–60

    Article  PubMed  CAS  Google Scholar 

  38. National Institute of Mental Health. Abnormal involuntary movement scale (AIMS). Washington, DC; US Government Printing Office, 1974. US Public Health Service publication no. MH-9-17

  39. Robertson JB, Treosti L, Walker KD. Successful use of high dose quetiapine in a patient with a psychiatric disorder resistant to olanzapine. Eur Neuropsychopharmacol 2000; 10(3): 319–20

    Article  Google Scholar 

  40. Arango C, Bobes J. Managing acute exacerbations of schizophrenia: focus on quetiapine. Curr Med Res Opin 2004; 20(5): 619–26

    Article  PubMed  CAS  Google Scholar 

  41. Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin 2004; 20(9): 1357–63

    Article  PubMed  CAS  Google Scholar 

  42. Buckley PF. Maintenance treatment for schizophrenia with quetiapine. Hum Psychopharmacol 2004; 19(2): 121–4

    Article  PubMed  CAS  Google Scholar 

  43. Kasper S, Brecher M, Fitton L, et al. Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment ofschizophrenia. Int Clin Psychopharmacol 2004; 19(5): 281–9

    Article  PubMed  Google Scholar 

  44. Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry 1999; 60 Suppl. 23: 5–9

    Google Scholar 

  45. Lieberman JA, McEvoy JP, Swartz MS, et al. Effectiveness of antipsychotic drags in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23

    Article  PubMed  CAS  Google Scholar 

  46. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600–10

    Article  PubMed  Google Scholar 

  47. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163(4): 611–22

    Article  PubMed  Google Scholar 

  48. McCue RE, Waheed R, Urcuyo L, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 2006; 189: 433–40

    Article  PubMed  Google Scholar 

  49. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24(2): 192–208

    Article  PubMed  CAS  Google Scholar 

  50. Ezewuzie N, Taylor D. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol 2006; 20(1): 86–90

    Article  PubMed  CAS  Google Scholar 

  51. Taylor D. Establishing a dose-response relationship for haloperidol decanoate. Psychiatr Bull 2005; 29(3): 104–7

    Article  Google Scholar 

  52. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry 2002; 10(5): 280–91

    Article  PubMed  Google Scholar 

  53. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157(4): 514–20

    Article  PubMed  CAS  Google Scholar 

  54. Seeman P, Tallerico T. Rapid release of antipsychotic drags from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999; 156(6): 876-84

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Professor Taylor has received consultancies fees, lecturing honoraria and/or research funding from AstraZeneca, Janssen-Cilag, Servier, Sanofi-Aventis, Lundbeck, Bristol-Myers Squibb, Novartis, Eli Lilly and Wyeth. He has also received royalties from Gaskell and Informa Healthcare. Ms Sparshatt and Ms Jones have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Pharmacy Department, Maudsley Hospital, Denmark Hill, London, SE5 8AZ, England

    Anna Sparshatt, Sarah Jones &  David Taylor

Authors
  1. Anna Sparshatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Taylor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sparshatt, A., Jones, S. & Taylor, D. Quetiapine. CNS Drugs 22, 49–68 (2008). https://doi.org/10.2165/00023210-200822010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200822010-00004

Keywords

Search

Navigation